Literature DB >> 9300746

Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.

Q T Le1, K K Fu, S Kroll, J K Ryu, J M Quivey, T S Meyler, R M Krieg, T L Phillips.   

Abstract

PURPOSE: To evaluate the influence of fraction size, overall time, total dose, and other prognostic factors on local control of T1 and T2 glottic carcinomas. METHODS AND MATERIALS: Between 1956 and 1995, 398 consecutive patients with early glottic carcinoma (315 T1 and 83 T2) were treated with once-a-day definitive radiotherapy at the University of California, San Francisco, and associated institutions. Treatment was delivered 5 days per week. Minimum tumor dose ranged from 46.6 to 77.6 Gy (median: 63 Gy). The fraction size was < 1.8 Gy in 146; 1.8-1.99 Gy in 128; 2.0-2.24 Gy in 62, and > or = 2.25 Gy in 62 patients. Overall time ranged from 34 to 75 days (median: 50 days). The majority of patients treated with a fraction size of 2.25 Gy completed therapy within 43 days. Median follow-up of all alive patients was 116 months (range 3-436 months).
RESULTS: Five-year local control was 85% for T1 and 70% for T2 glottic carcinomas (p = 0.0004). For T1 lesions, within the dose and time range evaluated, there was no apparent relationship between fraction size, overall time, total dose, and local control on multivariate analysis. Treatment era was the only significant prognostic factor (p = 0.02), and anterior commissure (AC) involvement was of borderline significance (p = 0.056). Five-year local control was 77% for patients treated between 1956-1970, 89% for between 1971-1980, and 91% for between 1981-1995; 80% for patients with AC involvement and 88% for those without. For T2 lesions, prognostic factors for local control on multivariate analysis were: overall time (p = 0.003), fraction size (p = 0.003), total dose (p = 0.01), impaired vocal cord mobility (p = 0.02), and subglottic extension (p = 0.04). Five-year local control was 100% for T2 lesions treated with overall time < or = 43 days vs. 84% for overall time > 43 days; 100% for fraction size > or = 2.25 Gy vs. 44% for fraction size < 1.8 Gy; 78% for total dose > 65 Gy vs. 60% for total dose < or = 65 Gy; 79% for normal cord mobility vs. 45% for impaired cord mobility, and 58% for lesions with subglottic extension vs. 77% for those without. The severe complication rate for the entire group was low: 1.8%.
CONCLUSIONS: Total dose, fraction size, and overall time were significant factors for local control of T2 but not T1 glottic carcinomas. Anterior commissure involvement was associated with decreased local control for T1 but not T2 lesions. For T1 lesions, local control improved over the treatment era. For T2 lesions, local control decreased with impaired cord mobility and subglottic extension.

Entities:  

Mesh:

Year:  1997        PMID: 9300746     DOI: 10.1016/s0360-3016(97)00284-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  38 in total

1.  Outcome of radiotherapy in T1 glottic carcinoma: a population-based study.

Authors:  Elisabeth Victoria Sjögren; Ruud G J Wiggenraad; Saskia Le Cessie; Simone Snijder; Jaqueline Pomp; Robert Jan Baatenburg de Jong
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-07       Impact factor: 2.503

2.  T1-2 glottic cancer treated with radiotherapy and/or surgery.

Authors:  Mohamed Shelan; Lukas Anschuetz; Adrian D Schubert; Beat Bojaxhiu; Alan Dal Pra; Frank Behrensmeier; Daniel M Aebersold; Roland Giger; Olgun Elicin
Journal:  Strahlenther Onkol       Date:  2017-05-04       Impact factor: 3.621

3.  Prognostic factors for local control in patients receiving radiation therapy for early glottic cancer: anterior commissure involvement and effect of chemoradiotherapy.

Authors:  Yosuke Kitani; Akira Kubota; Madoka Furukawa; Kaname Sato
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-01       Impact factor: 2.503

4.  Hypofractionated accelerated radiotherapy in T1-3 N0 cancer of the larynx: A prospective cohort study with historical controls.

Authors:  Zbigniew Szutkowski; Andrzej Kawecki; Andrzej Jarząbski; Zofia Laskus; Romuald Krajewski; Wojciech Michalski; Paweł Kukołowicz
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-20

5.  Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study.

Authors:  B G Salas-Salas; D J Domínguez-Nuez; R Cabrera; L Ferrera-Alayón; M Lloret; P C Lara
Journal:  Clin Transl Oncol       Date:  2019-06-01       Impact factor: 3.405

Review 6.  3D conformal hypofractionated radical radiotherapy in early glottic cancer.

Authors:  Ana Cristina Amado; Laurentiu Bujor; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-05-30

7.  Dynamic helical CT of T1 and T2 glottic carcinomas: predictive value for local control with radiation therapy.

Authors:  R Murakami; M Furusawa; Y Baba; R Nishimura; F Katsura; M Eura; K Masuyama; M Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

8.  Patterns of Care for Patients With Early-Stage Glottic Cancer Undergoing Definitive Radiation Therapy: A National Cancer Database Analysis.

Authors:  William A Stokes; Diana Abbott; Andy Phan; David Raben; Ryan M Lanning; Sana D Karam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-06       Impact factor: 7.038

9.  Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512).

Authors:  Andy Trotti; Qiang Zhang; Søren M Bentzen; Bahman Emami; M Elizabeth Hammond; Christopher U Jones; William H Morrison; Stephen M Sagar; John A Ridge; Karen K Fu; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

Review 10.  Head and neck cancer.

Authors:  Athanassios Argiris; Michalis V Karamouzis; David Raben; Robert L Ferris
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.